Belantamab mafodotin

• CAT Number: I042545
• CAS Number: 2050232-20-5
• Purity: ≥95%

Belantamab mafodotin (Cat No.: I042545) is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA), developed for the treatment of relapsed or refractory multiple myeloma. It combines a humanized anti-BCMA monoclonal antibody with the cytotoxic agent monomethyl auristatin F (MMAF), which disrupts microtubule dynamics, leading to apoptosis in malignant plasma cells. By selectively delivering the cytotoxin to BCMA-expressing cells, Belantamab mafodotin minimizes off-target effects. It represents a novel therapeutic approach in hematologic oncology and has shown promise in clinical trials.

Reference

[1]. Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221.
[Content Brief]

[2]. Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80(15):1607-1613.
[Content Brief]